STOCK TITAN

[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quest Diagnostics (DGX)Mark E. Delaney acquired 15 shares of common stock on 10/21/2025 at $189.077 per share via a dividend reinvestment plan. Following the transaction, he beneficially owns 7,530 shares, held directly. The filing notes the transaction is eligible for deferred reporting under Rule 16a-6 and was reported early.

Quest Diagnostics (DGX) ha riferito una transazione di insider su Modulo 4. Il Senior Vice President & Chief Commercial Officer Mark E. Delaney ha acquistato 15 azioni ordinarie in data 21/10/2025 al prezzo di $189.077 per azione tramite un piano di reinvestimento dei dividendi. A seguito della transazione, detiene direttamente 7.530 azioni in quanto beneficiario. Il deposito riporta che la transazione è eleggibile per la segnalazione differita ai sensi della Regola 16a-6 ed è stata segnalata precocemente.

Quest Diagnostics (DGX) informó una transacción de insider en el Formulario 4. El SVP y Chief Commercial Officer Mark E. Delaney adquirió 15 acciones ordinarias el 21/10/2025 a un precio de $189.077 por acción mediante un plan de reinversión de dividendos. Tras la transacción, posee de manera beneficial 7.530 acciones, directamente. El registro indica que la transacción es elegible para reporte diferido bajo la Regla 16a-6 y fue reportada con antelación.

Quest Diagnostics (DGX)는 Form 4에 내부자 거래를 보고했습니다. SVP 및 Chief Commercial Officer Mark E. Delaney15주의 보통주를 2025년 10월 21일에 주당 $189.077로 배당금 재투자 계획을 통해 취득했습니다. 거래 후 그는 직접 보유한 7,530주의 보통주를 유익하게 소유합니다. 제출 문서는 이 거래가 규칙 16a-6에 따라 이연 보고 대상이며 조기에 보고되었음을 명시합니다.

Quest Diagnostics (DGX) a signalé une transaction d’initié sur le formulaire 4. Le SVP & Chief Commercial Officer Mark E. Delaney a acquis 15 actions ordinaires le 21/10/2025 à $189.077 par action via un plan de réinvestissement des dividendes. Suite à la transaction, il détient avantageusement 7.530 actions, détenues directement. Le dépôt indique que la transaction est éligible à un report différé en vertu de la règle 16a-6 et a été signalée en avance.

Quest Diagnostics (DGX) hat eine Insider-Transaktion auf Formular 4 gemeldet. Der Senior Vice President & Chief Commercial Officer Mark E. Delaney erwarb 15 Stammaktien des Unternehmens am 21.10.2025 zu einem Preis von $189.077 pro Aktie über einen Dividenden-Reinvestitionsplan. Nach der Transaktion besitzt er direkt 7.530 Aktien. Die Einreichung vermerkt, dass die Transaktion gemäß Rule 16a-6 für eine verzögerte Berichterstattung geeignet ist und früh gemeldet wurde.

Quest Diagnostics (DGX) أبلغ عن عملية داخلية على النموذج 4. اشترى Mark E. Delaney، نائب الرئيس الأول والمدير التجاري التنفيذي 15 سهماً من الأسهم العادية في 21/10/2025 بسعر $189.077 للسهم من خلال خطة إعادة استثمار الأرباح. وبعد الصفقة، يملك 7.530 سهماً بشكل مستفيد، مباشرة. يذكر البيان أن الصفقة مؤهلة للإبلاغ المؤجل وفق القاعدة 16a-6 وتم الإبلاغ عنها مبكراً.

Positive
  • None.
Negative
  • None.

Quest Diagnostics (DGX) ha riferito una transazione di insider su Modulo 4. Il Senior Vice President & Chief Commercial Officer Mark E. Delaney ha acquistato 15 azioni ordinarie in data 21/10/2025 al prezzo di $189.077 per azione tramite un piano di reinvestimento dei dividendi. A seguito della transazione, detiene direttamente 7.530 azioni in quanto beneficiario. Il deposito riporta che la transazione è eleggibile per la segnalazione differita ai sensi della Regola 16a-6 ed è stata segnalata precocemente.

Quest Diagnostics (DGX) informó una transacción de insider en el Formulario 4. El SVP y Chief Commercial Officer Mark E. Delaney adquirió 15 acciones ordinarias el 21/10/2025 a un precio de $189.077 por acción mediante un plan de reinversión de dividendos. Tras la transacción, posee de manera beneficial 7.530 acciones, directamente. El registro indica que la transacción es elegible para reporte diferido bajo la Regla 16a-6 y fue reportada con antelación.

Quest Diagnostics (DGX)는 Form 4에 내부자 거래를 보고했습니다. SVP 및 Chief Commercial Officer Mark E. Delaney15주의 보통주를 2025년 10월 21일에 주당 $189.077로 배당금 재투자 계획을 통해 취득했습니다. 거래 후 그는 직접 보유한 7,530주의 보통주를 유익하게 소유합니다. 제출 문서는 이 거래가 규칙 16a-6에 따라 이연 보고 대상이며 조기에 보고되었음을 명시합니다.

Quest Diagnostics (DGX) a signalé une transaction d’initié sur le formulaire 4. Le SVP & Chief Commercial Officer Mark E. Delaney a acquis 15 actions ordinaires le 21/10/2025 à $189.077 par action via un plan de réinvestissement des dividendes. Suite à la transaction, il détient avantageusement 7.530 actions, détenues directement. Le dépôt indique que la transaction est éligible à un report différé en vertu de la règle 16a-6 et a été signalée en avance.

Quest Diagnostics (DGX) hat eine Insider-Transaktion auf Formular 4 gemeldet. Der Senior Vice President & Chief Commercial Officer Mark E. Delaney erwarb 15 Stammaktien des Unternehmens am 21.10.2025 zu einem Preis von $189.077 pro Aktie über einen Dividenden-Reinvestitionsplan. Nach der Transaktion besitzt er direkt 7.530 Aktien. Die Einreichung vermerkt, dass die Transaktion gemäß Rule 16a-6 für eine verzögerte Berichterstattung geeignet ist und früh gemeldet wurde.

Quest Diagnostics (DGX) أبلغ عن عملية داخلية على النموذج 4. اشترى Mark E. Delaney، نائب الرئيس الأول والمدير التجاري التنفيذي 15 سهماً من الأسهم العادية في 21/10/2025 بسعر $189.077 للسهم من خلال خطة إعادة استثمار الأرباح. وبعد الصفقة، يملك 7.530 سهماً بشكل مستفيد، مباشرة. يذكر البيان أن الصفقة مؤهلة للإبلاغ المؤجل وفق القاعدة 16a-6 وتم الإبلاغ عنها مبكراً.

Quest Diagnostics (DGX) 在 Form 4 上披露了内幕交易。高级副总裁兼首席商务官 Mark E. Delaney2025/10/21 通过股息再投资计划购得了 15 股普通股,价格为每股 $189.077。交易完成后,他直接持有的受益所有权为 7,530 股普通股。该申报文件指出该交易符合 Rule 16a-6 的延期披露条件,且已提前披露。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DELANEY MARK E

(Last) (First) (Middle)
500 PLAZA DRIVE
C/O QUEST DIAGNOSTICS INC

(Street)
SECAUCUS NJ 07094

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/21/2025 A V 15(1) A $189.077 7,530 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Remarks:
Sean D. Mersten, Attorney in Fact for Mark E. Delaney 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DGX disclose in this Form 4 filing?

An officer acquired 15 shares of common stock via a dividend reinvestment plan on 10/21/2025.

At what price were the DGX shares acquired?

The shares were acquired at $189.077 per share.

Who is the reporting person in DGX's Form 4?

The reporting person is Mark E. Delaney, SVP & Chief Commercial Officer.

How many DGX shares does the officer own after the transaction?

He beneficially owns 7,530 shares, held directly.

What was the method of acquisition in the DGX transaction?

Shares were acquired through a dividend reinvestment plan administered by the broker.

Was this DGX transaction reported early?

Yes. It is eligible for deferred reporting under Rule 16a-6 and was reported early.
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Latest News

DGX Latest SEC Filings

DGX Stock Data

20.38B
110.74M
0.4%
99.16%
3.8%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS